Lyell Immunopharma Inc. is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. Lyell Immunopharma Inc. is based in SOUTH SAN FRANCISCO, Calif.
| Revenue (Most Recent Fiscal Year) | $0.06M |
| Net Income (Most Recent Fiscal Year) | $-342.99M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 3611.67 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.58 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -552328.31% |
| Net Margin (Trailing 12 Months) | -552328.31% |
| Return on Equity (Trailing 12 Months) | -85.58% |
| Return on Assets (Trailing 12 Months) | -68.85% |
| Current Ratio (Most Recent Fiscal Quarter) | 7.65 |
| Quick Ratio (Most Recent Fiscal Quarter) | 7.65 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $15.56 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-2.89 |
| Earnings per Share (Most Recent Fiscal Year) | $-26.20 |
| Diluted Earnings per Share (Trailing 12 Months) | $-24.29 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 19.21M |
| Free Float | 14.93M |
| Market Capitalization | $216.70M |
| Average Volume (Last 20 Days) | 0.03M |
| Beta (Past 60 Months) | -0.19 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 22.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 66.05% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |